Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-3424 in relapsed or refractory acute lymphoblastic leukemia with high AKR1C3 expression
CTR20201915Phase 2Active
- Sponsor
- Accendatech
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odafosfamide in acute lymphoblastic leukemia (ALL), sponsored by Accendatech. Started Sep 2020; status: active.
02
Drugs
odafosfamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20201915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201915.